Hu-Lieskovan et al. provided a pre-clinical study that helps explain the efficacy of the triple-combination BRAFi + MEKi + anti-PD-1/PD-L1 in BRAFV600E+melanoma 115. This evidence concerns the gene CD274 and melanoma.